GREENWICH, Conn., Jan. 17, 2023 /PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational biopharmaceutical company, today announced the first participant has been dosed in their Phase 1 clinical trial of NYPRG-101 (2-bromo-d-lysergic acid diethylamide) in healthy adult participants.
Stephen Hurst has over thirty-five years' experience in the biopharmaceutical industry, including in senior executive positions at Sequential, Inc. and Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.), where he played a pivotal role in raising over $700 million in investment capital. In addition to formerly serving as a consultant to the World Bank and BIO Venture for Global Health, Hurst most recently served as co-CEO of Mind Medicine, a psychedelic pharmaceutical company he co-founded in 2019. From 2011 to 2019, Hurst served as CEO of Savant HWP, which he co-founded and oversaw the development and testing of psychedelic-based treatments to address substance use disorders.